NeuroBo Pharmaceuticals Q2 EPS $(0.18) Down From $(0.15) YoY
NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(0.18) per share. This is a 20 percent decrease over losses of $(0.15) per share from the same period last year.
NeuroBo Pharma European Patent Specification Doc For Co.’s ‘COMPOSITION CONTAINING PORIA COCOS BARK EXTRACT FOR PREVENTING, IMPROVING OR TREATING NEURODEGENERATIVE DISORDERS’
https://data.epo.org/publication-server/pdf-document?pn=3632454&ki=B1&cc=EP
38 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares jumped 218.7% to $6.57 after the company received a $28.3 million purchase order from Brazil's Bio-Manguinhos to purchase Chembio's DPP SARS-CoV-2 Antigen tests for delivery during 2021.
Mid-Morning Market Update: Markets Open Higher; Coca-Cola Tops Q2 Views
Following the market opening Wednesday, the Dow traded up 0.62% to 34,727.53 while the NASDAQ rose 0.40% to 14,557.04. The S&P also rose, gaining 0.52% to 4,345.65.
12 Health Care Stocks Moving In Wednesday’s Pre-Market Session
Gainers
Chembio Diagnostics (NASDAQ: CEMI) shares rose 102.91% to $4.18 during Wednesday's pre-market session. The market value of their outstanding shares is at $84.6 million.
Lexaria Bioscience (NASDAQ: LEXX) sharesGainers
28 Stocks Moving in Wednesday’s Pre-Market Session
Gainers
Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares rose 78.2% to $3.67 in pre-market trading after dropping more than 16% on Tuesday. Chembio’s filing recently showed registration for $60 million common stock offering.